Showing results (2121-2130 of 2,615) with videos related to

Sort By:
Pageof 262
The Science of the Total Environment|January 15, 2013
Associations between urban air pollution and pediatric asthma control in El Paso, TexasJennifer E Zora, Stefanie Ebelt Sarnat, Amit U Raysoni, et al.
Plant Disease|February 9, 2019
Virulence and Molecular Genotyping Studies of Sporisorium reilianum Isolates in SorghumLouis K Prom, Ramasamy Perumal, Saradha R Erattaimuthu, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 5, 2001
Psychosocial and risk behavior correlates of youth suicide attempts and suicidal ideationR A King, M Schwab-Stone, A J Flisher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 25, 2017
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid ArthritisMark C Genovese, Maria Greenwald, Christine Codding, et al.
Arthritis Care & Research|May 11, 2011
Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexateWilliam Rigby, Gianfranco Ferraccioli, Maria Greenwald, et al.
Cancer|October 25, 2011
Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatmentMichael Koscuiszka, David Hatcher, Paul J Christos, et al.
Schizophrenia Research|June 8, 2011
A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophreniaMatcheri S Keshavan, Shaun M Eack, Jessica A Wojtalik, et al.
Annals of the Rheumatic Diseases|December 21, 2016
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)A Kavanaugh, J Kremer, L Ponce, et al.
Journal of Comparative Pathology|October 13, 2014
Virulence of two strains of mycobacterium bovis in cattle following aerosol infectionW R Waters, T C Thacker, J T Nelson, et al.
British Journal of Clinical Pharmacology|February 25, 2016
A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritisStanley Cohen, Paul Emery, Maria Greenwald, et al.
Pageof 262